IDH1 and glioblastoma: Patients with unmethylated MGMT gene promoter with IDH1 mutation, treated with chemoradiotherapy including TMZ had a late tumor recurrence while glioblastomas with wildtype IDH1 and unmethylated MGMT gene promoter should be treated aggressively with radiotherapy and combined chemotherapies to delay tumor recurrence.